MGMT and central nervous system cancer: These findings contributed to MGMT promoter methylation’s prognostic and predictive importance in gliomas and led to the European Association of Neuro-Oncology (EANO) recommendation that MGMT testing in gliomas should be included in the treatment decision process [24].